Can I take Saxenda and metformin at the same time?

Yes. In patients with obesity and type 2 diabetes or prediabetes, this combination may be prescribed safely. There is no clinically significant drug-drug interaction.

Is Saxenda the same as Victoza?

Both contain liraglutide but at different doses. Saxenda (3.0 mg) is for weight management; Victoza (up to 1.8 mg) is for type 2 diabetes. They should never be used together.

Can this combination cause low blood sugar?

The inherent hypoglycemia risk is low. Risk increases if insulin or a sulfonylurea is added to the regimen.

What GI side effects should I expect?

Nausea, vomiting, diarrhea, and constipation are common with liraglutide, especially early in treatment. Metformin can also cause GI upset. Starting both at low doses and taking metformin with food can help.

Metformin & Liraglutide (Saxenda) Interaction

Minor

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Learn more about Metformin →Learn more about Liraglutide (Saxenda) →

Overview

Saxenda (liraglutide 3.0 mg daily) is approved for chronic weight management. In patients with obesity and type 2 diabetes, Saxenda may be used alongside metformin. This combination offers complementary metabolic benefits: GLP-1 mediated appetite suppression and weight loss plus metformin-driven insulin sensitization and glucose lowering.

How does this interaction occur?

Liraglutide at 3.0 mg activates GLP-1 receptors in the hypothalamus to reduce food intake and in the pancreas to enhance glucose-dependent insulin secretion. Metformin activates AMPK to reduce hepatic gluconeogenesis. These mechanisms are pharmacodynamically complementary without a pharmacokinetic interaction. Hypoglycemia risk is low without insulin or sulfonylurea co-prescription.

Clinical significance

The SCALE clinical trial program for Saxenda showed 5–9% body weight reduction over 56 weeks. In patients with prediabetes or type 2 diabetes on background metformin, the combination may confer additional weight loss and metabolic improvements. GI adverse effects are common with liraglutide and may overlap with metformin-related GI effects during initiation.

Management recommendations

Do not use Saxenda and Victoza (liraglutide for diabetes) simultaneously. Initiate Saxenda at 0.6 mg/day and escalate weekly per label. Metformin dose does not require adjustment. Counsel patients on GI side effects and importance of continued lifestyle intervention.

What to monitor

Body weight at monthly visits. Blood glucose and HbA1c in patients with diabetes or prediabetes. Renal function periodically (metformin). GI tolerability assessment each visit. Heart rate (liraglutide modestly increases heart rate).

Alternative options

Alternatives include Wegovy (semaglutide 2.4 mg weekly) for patients preferring weekly injection. For patients who cannot tolerate injectable GLP-1 agonists, phentermine/topiramate or other weight management options may be considered.

Frequently asked questions

References

[Regulatory] Liraglutide (Saxenda) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s011lbl.pdf Accessed 2026-03-01.
[Regulatory] Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. NEJM 2015. https://www.nejm.org/doi/10.1056/NEJMoa1411892 Accessed 2026-03-01.
[Regulatory] Metformin Hydrochloride FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026